Mizuho lowered the firm’s price target on Alkermes to $37 from $40 and keeps a Buy rating on the shares. The analyst expects a Q3 beat from Alkermes, driven by Invega royalties and solid Vivitrol and Lybalvi sales. However, the firm dropped the price target after incorporating the Vivitrol litigation patent settlement and European Union generic Xeplion competition into the model. ALKS-2680 could provide upside to the model, which currently reflects no value “for this blockbuster potential,” the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALKS:
- Alkermes initiated with a Neutral at UBS
- Mizuho expects ‘promising’ early data from Alkermes at World Sleep
- Alkermes gets few more years of Vivitrol exclusivity, says Piper Sandler
- Mizuho says Vivitrol patent settlement removes ‘key overhang’ for Alkermes
- Alkermes reaches settlement with Teva regarding VIVITROL patent litigation
